Exploitation of the Complement System by Oncogenic Kaposi's Sarcoma-Associated Herpesvirus for Cell Survival and Persistent Infection

PLoS Pathogens

Volumn 10, Issue 9, 2014, Pages

  Lee, Myung Shin ^a,b   Jones, Tiffany ^a   Song, Dae Yong ^b   Jang, Jae Hyuk ^b   Jung, Jae U ^a   Gao, Shou Jiang ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Eulji University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; DECAY ACCELERATING FACTOR; STAT3 PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5B; MESSENGER RNA; VIRUS PROTEIN;

ARTICLE; CELL SURVIVAL; CELL VIABILITY ASSAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOLYSIS; ENDOTHELIUM CELL; ENVIRONMENTAL EXPLOITATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE REPLICATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; MTT ASSAY; PERSISTENT VIRUS INFECTION; PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; APOPTOSIS; CELL CULTURE; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOLOGY; INFLAMMATION; KAPOSI SARCOMA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VIROLOGY; VIRUS LATENCY;

HUMAN HERPESVIRUS 8;

APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; COMPLEMENT C3B; COMPLEMENT C5B; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HERPESVIRUS 8, HUMAN; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; NEOVASCULARIZATION, PATHOLOGIC; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, KAPOSI; STAT3 TRANSCRIPTION FACTOR; VIRAL PROTEINS; VIRUS LATENCY;

EID: 84907584409     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004412     Document Type: Article

References (78)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM, (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. New Engl J Med 332: 1186–1191.
2. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, et al. (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 266: 1865–1869.
3. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, et al. (1995) Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 86: 1276–1280.
4. Cesarman E, (2011) Gammaherpesvirus and lymphoproliferative disorders in immunocompromised patients. Cancer Lett 305: 163–174.
5. Ganem D, (2010) KSHV and the pathogenesis of Kaposi's sarcoma: listening to human biology and medicine. J Clin Invest 120: 939–949.
6. Ye F, Lei X, Gao SJ, (2011) Mechanisms of Kaposi's sarcoma-associated herpesvirus latency and reactivation. Adv Virol 2011: pii: 193860.
7. Lee HR, Brulois K, Wong L, Jung JU, (2012) Modulation of immune system by Kaposi's sarcoma-associated herpesvirus: lessons from viral evasion strategies. Front Microbiol 3: 44.
8. Fujimuro M, Wu FY, ApRhys C, Kajumbula H, Young DB, et al. (2003) A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 9: 300–306.
9. Keller SA, Schattner EJ, Cesarman E, (2000) Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96: 2537–2542.
10. Liu J, Martin HJ, Liao G, Hayward SD, (2007) The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol 81: 10451–10459.
11. Uddin S, Hussain AR, Al-Hussein KA, Manogaran PS, Wickrema A, et al. (2005) Inhibition of phosphatidylinositol 3′-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin Cancer Res 11: 3102–3108.
12. Xie J, Ajibade AO, Ye F, Kuhne K, Gao SJ, (2008) Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology 371: 139–154.
13. Moody R, Zhu Y, Huang Y, Cui X, Jones T, et al. (2013) KSHV microRNAs mediate cellular transformation and tumorigenesis by redundantly targeting cell growth and survival pathways. PLoS Pathog 9: e1003857.
14. Aoki Y, Feldman GM, Tosato G, (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101: 1535–1542.
15. Molden J, Chang Y, You Y, Moore PS, Goldsmith MA, (1997) A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 272: 19625–19631.
16. Punjabi AS, Carroll PA, Chen L, Lagunoff M, (2007) Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J Virol 81: 2449–2458.
17. Walport MJ, (2001) Complement. Second of two parts. New Engl J Med 344: 1140–1144.
18. Walport MJ, (2001) Complement. First of two parts. New Engl J Med 344: 1058–1066.
19. Rus H, Cudrici C, Niculescu F, (2005) The role of the complement system in innate immunity. Immunol Res 33: 103–112.
20. Zipfel PF, Skerka C, (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729–740.
21. Tegla CA, Cudrici C, Patel S, Trippe R, Rus V, et al. (2011) Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 51: 45–60.
22. Kouser L, Abdul-Aziz M, Nayak A, Stover CM, Sim RB, et al. (2013) Properdin and factor h: opposing players on the alternative complement pathway “see-saw”. Front Immunol 4: 93.
23. Morgan HP, Schmidt CQ, Guariento M, Blaum BS, Gillespie D, et al. (2011) Structural basis for engagement by complement factor H of C3b on a self surface. Nat Struct Mol Biol 18: 463–470.
24. Pangburn MK, Müller-Eberhard HJ, (1984) The alternative pathway of complement. Springer Semin Immunol 7: 163–192.
25. Risitano AM, (2013) Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies. Adv Exp Med Biol 734: 155–172.
26. Wenzel K, Zabojszcza J, Carl M, Taubert S, Lass A, et al. (2005) Increased susceptibility to complement attack due to down-regulation of decay-accelerating factor/CD55 in dysferlin-deficient muscular dystrophy. J Immunol 175: 6219–6225.
27. Ostrand-Rosenberg S, (2008) Cancer and complement. Nature Biotechnol 26: 1348–1349.
28. Schraufstatter IU, Trieu K, Sikora L, Sriramarao P, DiScipio R, (2002) Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol 169: 2102–2110.
29. Rus HG, Niculescu FI, Shin ML, (2001) Role of the C5b-9 complement complex in cell cycle and apoptosis. Immunol Rev 180: 49–55.
30. Fosbrink M, Niculescu F, Rus H, (2005) The role of c5b-9 terminal complement complex in activation of the cell cycle and transcription. Immunol Res 31: 37–46.
31. Fosbrink M, Niculescu F, Rus V, Shin ML, Rus H, (2006) C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J Biol Chem 281: 19009–19018.
32. Halperin JA, Taratuska A, Nicholson-Weller A, (1993) Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 91: 1974–1978.
33. Kunchithapautham K, Rohrer B, (2011) Sublytic membrane-attack-complex (MAC) activation alters regulated rather than constitutive vascular endothelial growth factor (VEGF) secretion in retinal pigment epithelium monolayers. J Biol Chem 286: 23717–23724.
34. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT, (2010) Cancer and the complement cascade. Mol Cancer Res: MCR 8: 1453–1465.
35. Ricklin D, Lambris JD, (2013) Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol 190: 3831–3838.
36. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, et al. (1996) Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. New Engl J Med 335: 233–241.
37. Zhou F-C, Zhang Y-J, Deng J-H, Wang X-P, Pan H-Y, et al. (2002) Efficient infection by a recombinant Kaposi's sarcoma-associated herpesvirus cloned in a bacterial artificial chromosome: application for genetic analysis. J Virol 76: 6185–6196.
38. Lagunoff M, Bechtel J, Venetsanakos E, Roy A-M, Abbey N, et al. (2002) De novo infection and serial transmission of Kaposi's sarcoma-associated herpesvirus in cultured endothelial cells. J Virol 76: 2440–2448.
39. An F-Q, Folarin HM, Compitello N, Roth J, Gerson SL, et al. (2006) Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. J Virol 80: 4833–4846.
40. Kochi SK, Johnson RC, (1988) Role of immunoglobulin G in killing of Borrelia burgdorferi by the classical complement pathway. Infect Immun 56: 314–321.
41. Des Prez RM, Bryan CS, Hawiger J, Colley DG, (1975) Function of the classical and alternate pathways of human complement in serum treated with ethylene glycol tetraacetic acid and MgCl2-ethylene glycol tetraacetic acid. Infect Immun 11: 1235–1243.
42. Spiller OB, Blackbourn DJ, Mark L, Proctor DG, Blom AM, (2003) Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus. J Biol Chem 278: 9283–9289.
43. Spiller OB, Robinson M, O'Donnell E, Milligan S, Morgan BP, et al. (2003) Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein. J Virol 77: 592–599.
44. Wu J, Wu YQ, Ricklin D, Janssen BJ, Lambris JD, et al. (2009) Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol 10: 728–733.
45. Perkins SJ, Nan R, Okemefuna AI, Li K, Khan S, et al. (2010) Multiple interactions of complement Factor H with its ligands in solution: a progress report. Adv Exp Med Biol 703: 25–47.
46. Cosyns JP, Kazatchkine MD, Bhakdi S, Mandet C, Grossetete J, et al. (1986) Immunohistochemical analysis of C3 cleavage fragments, factor H, and the C5b-9 terminal complex of complement in de novo membranous glomerulonephritis occurring in patients with renal transplant. Clin Nephrol 26: 203–208.
47. Levy DE, Darnell JE, (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651–662.
48. King CA, (2013) Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28. J Virol 87: 8779–8791.
49. Alcami A, Koszinowski UH, (2000) Viral mechanisms of immune evasion. Immunol Today 21: 447–455.
50. Cooper PD, (1985) Complement and cancer: activation of the alternative pathway as a theoretical base for immunotherapy. Adv Immun Cancer Ther 1: 125–166.
51. Kolev M, Towner L, Donev R, (2011) Complement in cancer and cancer immunotherapy. Arch Immunol Ther Exp 59: 407–419.
52. Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, et al. (1996) Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 348: 1133–1138.
53. Guadalupe M, Pollock BH, Westbrook S, Redding S, Bullock D, et al. (2011) Risk factors influencing antibody responses to Kaposi's sarcoma-associated herpesvirus latent and lytic antigens in patients under antiretroviral therapy. J AIDS 56: 83–90.
54. Thurman JM, Holers VM, (2006) The central role of the alternative complement pathway in human disease. J Immunol 176: 1305–1310.
55. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, et al. (2005) Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419–421.
56. Edwards AO, Ritter R, 3rdAbel KJ, Manning A, Panhuysen C, et al. (2005) Complement factor H polymorphism and age-related macular degeneration. Science 308: 421–424.
57. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, et al. (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102: 7227–7232.
58. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, et al. (2005) Complement factor H polymorphism in age-related macular degeneration. Science 308: 385–389.
59. Cazander G, Jukema GN, Nibbering PH, (2012) Complement activation and inhibition in wound healing. Clin Dev Immunol 2012: 534291.
60. Fujita T, Hemmi S, Kajiwara M, Yabuki M, Fuke Y, et al. (2012) Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev 29: 220–226.
61. Lucas SD, Karlsson-Parra A, Nilsson B, Grimelius L, Akerström G, et al. (1996) Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Human Pathol 27: 1329–1335.
62. Niculescu F, Rus HG, Retegan M, Vlaicu R, (1992) Persistent complement activation on tumor cells in breast cancer. Am J Pathol 140: 1039–1043.
63. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP, (1996) Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 149: 129–142.
64. Coussens LM, Werb Z, (2002) Inflammation and cancer. Nature 420: 860–867.
65. Grivennikov SI, Karin M, (2010) Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 20: 65–71.
66. Douglas JL, Gustin JK, Moses AV, Dezube BJ, Pantanowitz L, (2010) Kaposi's sarcoma pathogenesis: a triad of viral infection, oncogenesis and chronic inflammation. Transl Biomed 1 (2010)
67. Lutticken C, Wegenka UM, Yuan J, Buschmann J, Schindler C, et al. (1994) Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130. Science 263: 89–92.
68. Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, et al. (1994) Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell 77: 63–71.
69. Benzaquen LR, Nicholson-Weller A, Halperin JA, (1994) Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells. J Exp Med 179: 985–992.
70. Deo DD, Axelrad TW, Robert EG, Marcheselli V, Bazan NG, et al. (2002) Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism. J Biol Chem 277: 21237–21245.
71. Sachsenmaier C, Sadowski HB, Cooper JA, (1999) STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation. Oncogene 18: 3583–3592.
72. Werner S, Hofschneider PH, Roth WK, (1989) Cells derived from sporadic and AIDS-related Kaposi's sarcoma reveal identical cytochemical and molecular properties in vitro. Int J Cancer 43: 1137–1144.
73. Roth WK, Werner S, Schirren CG, Hofschneider PH, (1989) Depletion of PDGF from serum inhibits growth of AIDS-related and sporadic Kaposi's sarcoma cells in culture. Oncogene 4: 483–487.
74. Delli Bovi P, Curatola AM, Kern FG, Greco A, Ittmann M, et al. (1987) An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell 50: 729–737.
75. Delli-Bovi P, Curatola AM, Newman KM, Sato Y, Moscatelli D, et al. (1988) Processing, secretion, and biological properties of a novel growth factor of the fibroblast growth factor family with oncogenic potential. Mol Cell Biol 8: 2933–2941.
76. Niculescu F, Soane L, Badea T, Shin M, Rus H, (1999) Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells. Immunopharmacology 42: 187–193.
77. Ye FC, Blackbourn DJ, Mengel M, Xie JP, Qian LW, et al. (2007) Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1. J Virol 81: 3980–3991.
78. Yoo S-M, Zhou F-C, Ye F-C, Pan H-Y, Gao S-J, (2005) Early and sustained expression of latent and host modulating genes in coordinated transcriptional program of KSHV productive primary infection of human primary endothelial cells. Virology 343: 47–64.